Nasopharyngeal Carcinoma, Radiation-Induced Xerostomia
Conditions
Interventions
Crotrol Group:Placebo, same administration as Celecoxib capsules.
Experimental Group:Celecoxib capsules, 200 mg, twice daily, taken orally after breakfast and dinner, starting on the first day of radiotherapy and continuing until the end of radiotherapy.
Sponsors
The First Hospital of Jiaxing
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with nasopharyngeal carcinoma (NPC) who have a definite pathological diagnosis and have not received radiotherapy 2: 2. Patients without contraindications to radiotherapy and undergoing their first course of radiotherapy 3: 3. Patients with an expected survival time > 6 months 4: 4. Age between 18 and 80 years, regardless of gender 5: 5. Patients in good general condition with an ECOG performance status score of 0-2; 6. Patients who have signed informed consent, have normal cognitive abilities, no intellectual or psychiatric disorders, normal language expression ability, and can complete the questionnaire independently or with assistance from others.
Exclusion criteria
Exclusion criteria: 1. Patients with a prior diagnosis of conditions that may exacerbate or confound post-radiotherapy adverse reactions, including Sjögren's syndrome, Behçet's disease, or history of submandibular or parotid gland surgery; 2. Patients with severe impairment of cardiac, hepatic, renal, or hematopoietic function (cardiac function NYHA Class III-IV; Hepatic function Child-Pugh Class B/C; Renal function eGFR < 30 mL/min/1.73m²); 3. History of hypersensitivity to celecoxib, sulfonamides, aspirin, or other NSAIDs; 4. History of gastrointestinal ulcer or gastrointestinal bleeding; 5. History of stroke, myocardial infarction, or coronary artery bypass grafting (CABG); 6. Pregnant or lactating women; 7. Patients with multiple primary cancers; 8. Long-term use of NSAIDs or glucocorticoids within the past month; 9. Any other condition deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dry mouth sevsrity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute Radiation-Induced Oropharyngeal Mucosal Injury Severity;Doppler Ultrasound Assessment of Parotid Gland Function;Onset Time and Cumulative Radiation Dose of Radiation-Induced Xerostomia; | — |
Countries
China
Contacts
Public ContactSong Binbin
The First Hospital of Jiaxing
Outcome results
None listed